These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36267794)

  • 1. Challenges and opportunities in biomarker-driven trials: adaptive randomization.
    Park Y
    Ann Transl Med; 2022 Sep; 10(18):1035. PubMed ID: 36267794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Personalized Risk-Based Screening Design for Comparative Two-Arm Group Sequential Clinical Trials.
    Park Y
    J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bias in retrospective analyses of biomarker effect using data from an outcome-adaptive randomized trial.
    Ji L; McShane LM; Krailo M; Sposto R
    Clin Trials; 2019 Dec; 16(6):599-609. PubMed ID: 31581815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
    Zhou X; Liu S; Kim ES; Herbst RS; Lee JJ
    Clin Trials; 2008; 5(3):181-93. PubMed ID: 18559407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simulation study for comparing testing statistics in response-adaptive randomization.
    Gu X; Lee JJ
    BMC Med Res Methodol; 2010 Jun; 10():48. PubMed ID: 20525382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations.
    Hu C; Dignam JJ
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32923854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian biomarker-driven outcome-adaptive randomization with an imperfect biomarker assay.
    Garcia Barrado L; Burzykowski T
    Clin Trials; 2021 Apr; 18(2):137-146. PubMed ID: 33231131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Signature Enrichment Design with Bayesian Adaptive Randomization.
    Xia F; George SL; Ning J; Li L; Huang X
    J Appl Stat; 2021; 48(6):1091-1110. PubMed ID: 34024982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A group sequential, response-adaptive design for randomized clinical trials.
    Karrison TG; Huo D; Chappell R
    Control Clin Trials; 2003 Oct; 24(5):506-22. PubMed ID: 14500050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A simulation study of outcome adaptive randomization in multi-arm clinical trials.
    Wathen JK; Thall PF
    Clin Trials; 2017 Oct; 14(5):432-440. PubMed ID: 28982263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical trial designs for testing biomarker-based personalized therapies.
    Lai TL; Lavori PW; Shih MC; Sikic BI
    Clin Trials; 2012 Apr; 9(2):141-54. PubMed ID: 22397801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint.
    Yin G; Chen N; Lee JJ
    Stat Biosci; 2018 Aug; 10(2):420-438. PubMed ID: 30559900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian two-stage sequential enrichment design for biomarker-guided phase II trials for anticancer therapies.
    Su L; Chen X; Zhang J; Gao J; Yan F
    Biom J; 2022 Oct; 64(7):1192-1206. PubMed ID: 35578917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expected Value of Sample Information to Guide the Design of Group Sequential Clinical Trials.
    Flight L; Julious S; Brennan A; Todd S
    Med Decis Making; 2022 May; 42(4):461-473. PubMed ID: 34859693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inference under covariate-adaptive randomization: A simulation study.
    Callegaro A; Harsha Shree BS; Karkada N
    Stat Methods Med Res; 2021 Apr; 30(4):1072-1080. PubMed ID: 33504277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of covariate adjustment at randomization and analysis for binary outcomes: understanding differences between superiority and noninferiority trials.
    Nicholas K; Yeatts SD; Zhao W; Ciolino J; Borg K; Durkalski V
    Stat Med; 2015 May; 34(11):1834-40. PubMed ID: 25641057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of methodological considerations regarding adaptive stopping, arm dropping, and randomization in clinical trials.
    Granholm A; Kaas-Hansen BS; Lange T; Schjørring OL; Andersen LW; Perner A; Jensen AKG; Møller MH
    J Clin Epidemiol; 2023 Jan; 153():45-54. PubMed ID: 36400262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inference under Covariate-Adaptive Randomization.
    Bugni FA; Canay IA; Shaikh AM
    J Am Stat Assoc; 2018; 113(524):1784-1796. PubMed ID: 30906087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative models and randomization techniques for Bayesian response-adaptive randomization with binary outcomes.
    Proper J; Connett J; Murray T
    Clin Trials; 2021 Aug; 18(4):417-426. PubMed ID: 33926267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.